$HALB Offers Alt-Path for Reopening Trade with Strong Bearing

GregFolin tarafından
HHALB is positioned as an alternative to traditional vaccine solutions, which is a rare narrative, potentially conferring scarcity value on shares (contingent on efficacy and execution.

The company that holds the exclusive rights to a number of COVID-19 “extracorporeal treatment” technology provisional patent applications ("Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus," and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans," "Nasal Spray to Prevent the Transmission of Covid-19," and "Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus").
Beyond Technical AnalysisChart PatternsHALBTechnical Indicators
GregFolin

Feragatname